Emerging biomarkers for the detection of cardiovascular diseases
Tóm tắt
The prevalence of cardiovascular disease (CVD) has been continuously increasing, and this trend is projected to continue. CVD is rapidly becoming a significant public health issue. Every year there is a spike in hospital cases of CVD, a critical health concern in lower- and middle-income countries. Based on identification of novel biomarkers, it would be necessary to study and evaluate the diagnostic requirements or CVD to expedite early detection.
The literature review was written using a wide range of sources, such as well-known medical journals, electronic databases, manuscripts, texts, and other writings from the university library. After that, we analysed the specific markers of CVD and compiled a systematic review. A growing body of clinical research aims to identify people who are at risk for cardiovascular disease by looking for biomolecules. A small number of biomarkers have been shown to be useful and reliable in medicine. Biomarkers can be used for a variety of clinical applications, such as predicting heart disease risk, diagnosing disease, or predicting outcomes. As a result of the ability for a single molecule to act as a biomarker, its usefulness in medicine is expected to increase significantly.
Based on assessing the current trends in the application of CVD markers, we discussed and described the requirements for the application of CVD biomarkers in coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other cardiovascular illnesses. Furthermore, the current review focuses on biomarkers for CVD and the procedures that should be considered to establish the comprehensive nature of the expression of biomarkers for cardiovascular illness.
Từ khóa
Tài liệu tham khảo
Al-Mawali A (2015) Non-communicable diseases: shining a light on cardiovascular disease, Oman’s biggest killer. Oman Med J 30(4):227
Thomas H, Diamond J, Vieco A, Chaudhuri S, Shinnar E, Cromer S, Perel P, Mensah GA, Narula J, Johnson CO (2018) Global atlas of cardiovascular disease. Glob Heart 13:143–163
Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A (2016) Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 4(13):256
van Kimmenade RR, Januzzi JL Jr (2012) Emerging biomarkers in heart failure. Clin Chem 58(1):127–138
Haider A, Bengs S, Luu J, Osto E, Siller-Matula JM, Muka T, Gebhard C (2020) Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome. Eur Heart J 41(13):1328–1336
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379(22):2097–2107
AlGawwam G, Shake ME (2021) Evaluation of glycogen phosphorylase BB (GPBB) level in serum as marker in diagnosis of acute ischemic stroke. Indian J Forensic Med Toxicol 15(3):1603–1608
El-Nagdy SA, Elfakharany Y, Etewa R (2020) Role of glycogen phosphorylase in prediction of cardiotoxicity associated with acute carbon monoxide poisoning. Zagazig J Forensic Med 18(2):59–74
Migocka-Patrzałek M, Elias M (2021) Muscle glycogen phosphorylase and its functional partners in health and disease. Cells 10(4):883
Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O (2005) Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51(5):810–824
Krause E-G, Rabitzsch G, Noll F, Mair J, Puschendorf B (1996) Glycogen phosphorylase isoenzyme BB in diagnosis of myocardial ischaemic injury and infarction. Mol Cell Biochem 160(161):289–295
Singh N, Rathore V, Mahat RK, Rastogi P (2018) Glycogen phosphorylase BB: a more sensitive and specific marker than other cardiac markers for early diagnosis of acute myocardial infarction. Indian J Clin Biochem 33(3):356–360
Newgard CB, Hwang PK, Fletterick RJ (1989) The family of glycogen phosphorylases: structure and functio. Crit Rev Biochem Mol Biol 24(1):69–99
Park K-Y, Ay I, Avery R, Caceres JA, Siket MS, Pontes-Neto OM, Zheng H, Rost NS, Furie KL, Sorensen AG (2018) New biomarker for acute ischaemic stroke: plasma glycogen phosphorylase isoenzyme BB. J Neurol Neurosurg Psychiatry 89(4):404–409
Peetz D, Post F, Schinzel H, Schweigert R, Schollmayer C, Steinbach K, Dati F, Noll F, Lackner KJ (2005) Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med (CCLM) 43(12):1351–1358
Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann U, Krause E-G, Dienstl F, Puschendorf B (1995) Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 41(7):966–978
Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann U, Krause E-G, Dienstl F, Puschendorf B (1993) Isoenzyme BB of glycogen phosphorylase b and myocardial infarction. Lancet 341(8851):1032–1033
Wild PS, Schnabel RB, Lubos E, Zeller T, Sinning CR, Keller T, Tzikas S, Lackner KJ, Peetz D, Rupprecht HJ (2012) Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the Athero Gene Study. Clin Chem 58(1):226–236
Parsanathan R, Jain SK (2020) Novel invasive and noninvasive cardiac-specific biomarkers in obesity and cardiovascular diseases. Metab Syndr Relat Disord 18(1):10–30
Dolci A, Panteghini M (2006) The exciting story of cardiac biomarkers: from retrospective detection to gold diagnostic standard for acute myocardial infarction and more. Clin Chim Acta 369(2):179–187
Ladenson JH (2007) A personal history of markers of myocyte injury [myocardial infarction]. Clin Chim Acta 381(1):3–8
Ruzich RS (1992) Cardiac enzymes: how to use serial determinations to confirm acute myocardial infarction. Postgrad Med 92(7):85–92
Lee N, Barthel SR, Schatton T (2014) Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Invest 94(1):13–30
Series CC, Challenge E, Mind OM, Doodle C (1979) Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 59(3):607–609
Yamaguchi S, Abe M, Arakaki T, Arasaki O, Shimabukuro M (2020) Prognostic value of lactate dehydrogenase for mid-term mortality in acute decompensated heart failure: a comparison to established biomarkers and brain natriuretic peptide. Heart Lung Circ 29(9):1318–1327
Aly M, Nayel M, Salama A, Ghazy E, Elshahawy I (2020) Cardiac troponin I as a cardiac biomarker has prognostic and predictive value for poor survival in Egyptian buffalo calves with foot-and-mouth disease. Vet World 13(5):890
Schmiechen NJ, Han C, Milzman DP (1997) ED use of rapid lactate to evaluate patients with acute chest pain. Ann Emerg Med 30(5):571–577
Silagi ES, Batista P, Shapiro IM, Risbud MV (2018) Expression of carbonic anhydrase III, a nucleus pulposus phenotypic marker, is hypoxia-responsive and confers protection from oxidative stress-induced cell death. Sci Rep 8(1):1–13
Dowling P, Gargan S, Zweyer M, Sabir H, Swandulla D, Ohlendieck K (2021) Proteomic profiling of carbonic anhydrase CA3 in skeletal muscle. Expert Rev Proteomics 18:1–14
Zamanova S, Shabana AM, Mondal UK, Ilies MA (2019) Carbonic anhydrases as disease markers. Expert Opin Ther Pat 29(7):509–533
Feng H-Z, Jin J-P (2019) Transgenic expression of carbonic anhydrase III in cardiac muscle demonstrates a mechanism to tolerate acidosis. Am J Physiol Cell Physiol 317(5):C922–C931
Zhang X-M, Tao Y-H, Zhou X-L, Shang X-L, Gong X-B, Liu Y-C, Huang Y-Y, Chen G, Yu Z-Y, Wang J-T (2021) The role of carbonic anhydrase III and autophagy in type 2 diabetes with cardio-cerebrovascular disease. Metab Brain Dis 36(8):2329–2341
Kim YS, Karisa N, Jeon WY, Lee H, Kim Y-c, Ahn J (2019) High-level production of N-terminal pro-brain natriuretic peptide, as a calibrant of heart failure diagnosis, Escherichia coli. Appl Microbiol Biotechnol 103(12):4779–4788
York MK, Gupta DK, Reynolds CF, Farber-Eger E, Wells QS, Bachmann KN, Xu M, Harrell FE, Wang TJ (2018) B-type natriuretic peptide levels and mortality in patients with and without heart failure. J Am Coll Cardiol 71(19):2079–2088
Almeida Junior GLGd, Braga F, Jorge JK, Nobre GF, Kalichsztein M, Faria PdMPd, Bussade B, Penna GL, Alves VO, Pereira MA (2020) Prognostic value of troponin-T and B-type natriuretic peptide in patients hospitalized for COVID-19. Arq Bras Cardiol 115:660–666
Ghomian N, Vakilian F, Shahri B, Rostaminejad V, Khadem-Rezaiyan M (2019) Can brain natriuretic peptide predict cardiovascular complications in severe preeclampsia? A case-control study. Int J Reprod BioMed 17(4):271
Wong Y-K, Cheung CY, Tang CS, Hai JS, Lee C-H, Lau K-K, Au K-W, Cheung BM, Sham P-C, Xu A (2019) High-sensitivity Troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus. Cardiovasc Diabetol 18(1):1–12
Li X, Liu C, Mao Z, Qi S, Song R, Zhou F (2020) Brain natriuretic peptide for predicting contrast-induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography: a systematic review and Meta-analysis. J Int Cardiol 2020:1035089
Cui K, Huang W, Fan J, Lei H (2018) Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction. Medicine 97(36):e12277
Pervez MO, Winther JA, Brynildsen J, Strand H, Christensen G, Høiseth AD, Myhre PL, Røysland R, Lyngbakken MN, Omland T (2018) Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study. Biomarkers 23(7):654–663
Gauffin E, Chisalita SI, Engvall J, Nyström FH, Östgren CJ (2021) Plasma mid-regional pro-atrial natriuretic peptide predicts cardiovascular events in patients with type 2 diabetes independently of subclinical organ damage. Diabetes Res Clin Pract 182:109095
Francis GS, Felker GM, Tang WW (2016) A test in context: critical evaluation of natriuretic peptide testing in heart failure. J Am Coll Cardiol 67(3):330–337
Koyama T, Kuriyama N, Suzuki Y, Saito S, Tanaka R, Iwao M, Tanaka M, Maki T, Itoh H, Ihara M (2021) Mid-regional pro-adrenomedullin is a novel biomarker for arterial stiffness as the criterion for vascular failure in a cross-sectional study. Sci Rep 11(1):1–7
Czajkowska K, Zbroch E, Bielach-Bazyluk A, Mitrosz K, Bujno E, Kakareko K, Rydzewska-Rosolowska A, Hryszko T (2021) Mid-regional proadrenomedullin as a new biomarker of kidney and cardiovascular diseases—is it the future? J Clin Med 10(3):524
van Oers JA, Kluiters Y, Bons JA, de Jongh M, Pouwels S, Ramnarain D, de Lange DW, de Grooth H-J, Girbes AR (2021) Endothelium-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: a prospective cohort study. J Crit Care 66:173–180
Bustamante A, García-Berrocoso T, Penalba A, Giralt D, Simats A, Muchada M, Zapata E, Rubiera M, Montaner J (2017) Sepsis biomarkers reprofiling to predict stroke-associated infections. J Neuroimmunol 312:19–23
Dres M, Hausfater P, Foissac F, Bernard M, Joly L-M, Sebbane M, Philippon A-L, Gil-Jardiné C, Schmidt J, Maignan M (2017) Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study. Int J Chron Obstr Pulm Dis 12:1047
Lopes D, Falcao LM (2017) Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis. Rev Port Cardiol (English Edition) 36(6):465–472
Hülsmann M, Stanek B, Frey B, Sturm B, Putz D, Kos T, Berger R, Woloszczuk W, Maurer G, Pacher R (1998) Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 32(6):1695–1700
Kempf T, Wollert KC (2009) Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz 34(8):594–599
Jankowich M, Choudhary G (2020) Endothelin-1 levels and cardiovascular events. Trends Cardiovasc Med 30(1):1–8
Obokata M, Kane GC, Reddy YN, Melenovsky V, Olson TP, Jarolim P, Borlaug BA (2019) The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction. Eur Heart J 40(45):3707–3717
Then C, Thorand B, Then HL, Meisinger C, Heier M, Peters A, Koenig W, Rathmann W, Bidlingmaier M, Lechner A (2020) Serum uromodulin is inversely associated with arterial hypertension and the vasoconstrictive prohormone CT-proET-1 in the population-based KORA F4 study. PLoS ONE 15(8):e0237364
Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P, Solomon SD, Pfeffer MA, Braunwald E (2012) Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 125(2):233–240
Al-Hadi HA, Fox KA (2009) Cardiac markers in the early diagnosis and management of patients with acute coronary syndrome. Sultan Qaboos Univ Med J 9(3):231
Guzy PM (1977) Creatine phosphokinase-MB (CPK-MB) and the diagnosis of myocardial infarction. West J Med 127(6):455
Elliott B, Jepson E, Wilkinson J (1962) Serum alpha-hydroxybutyrate dehydrogenase-a new test with improved specificity for myocardial lesions. Clin Sci 23(2):305
Rosalki S (1963) Serum α-hydroxybutyrate dehydrogenase: a new test for myocardial infarction. Br Heart J 25(6):795
Elliott B, Wilkinson J (1963) Serum alpha-hydroxybutyrate dehydrogenase in diseases other than myocardial infarction. Clin Sci 24(3):343–350
Haltern G, Peiniger S, Bufe A, Reiss G, Gülker H, Scheffold T (2010) Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardiol 105(1):1–9
Mad P, Domanovits H, Fazelnia C, Stiassny K, Russmüller G, Cseh A, Sodeck G, Binder T, Christ G, Szekeres T (2007) Human heart-type fatty-acid-binding protein as a point-of-care test in the early diagnosis of acute myocardial infarction. J Assoc Physicians 100(4):203–210
Ruzgar O, Bilge AK, Bugra Z, Umman S, Yilmaz E, Ozben B, Umman B, Meric M (2006) The use of human heart-type fatty acid-binding protein as an early diagnostic biochemical marker of myocardial necrosis in patients with acute coronary syndrome, and its comparison with troponin-T and creatine kinase–myocardial band. Heart Vessels 21(5):309–314
Clearfield MB (2005) C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 105(9):409–416
Chandra P, Suman P, Airon H, Mukherjee M, Kumar P (2014) Prospects and advancements in C-reactive protein detection. World J Methodol 4(1):1
Chrysohoou C, Pitsavos C, Barbetseas J, Kotroyiannis I, Brili S, Vasiliadou K, Papadimitriou L, Stefanadis C (2009) Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). Heart Vessels 24(1):22–26
Rivera M, Taléns-Visconti R, Sirera R, Bertomeu V, Salvador A, Cortés R, de Burgos FG, Climent V, Payá R, Martinez-Dolz L (2004) Soluble TNF-α and interleukin-6 receptors in the urine of heart failure patients. Their clinical value and relationship with plasma levels. Eur J Heart Fail 6(7):877–882
Wollert KC, Drexler H (2001) The role of interleukin-6 in the failing heart. Heart Fail Rev 6(2):95–103
Gabriele P, Zhi Fang S, Tonny DTT, Carsten K, Hideo AB, Michael E, Markus F, Thomas W, Hans HS, Mario CD (2001) Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail 3(4):415–421
Raymond RJ, Dehmer GJ, Theoharides TC, Deliargyris EN (2001) Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J 141(3):435–438
Pudil R, Tichý M, Andrýs C, Rehácek V, Bláha V, Vojácek J, Palicka V (2010) Plasma interleukin-6 level is associated with NT-proBNP level and predicts short-and long-term mortality in patients with acute heart failure. Acta Medica (Hradec Kralove) 53(4):225–228
Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I (2007) Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 27(1):161–167
Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, Pasqualini F, Signorini S, Soldateschi D (2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110(16):2349–2354
Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, Sagara M, Kubota I (2008) Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 155(1):75–81
Knoflach M, Kiechl S, Mantovani A, Cuccovillo I, Bottazzi B, Xu Q, Xiao Q, Gasperi A, Mayr A, Kehrer M (2012) Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies. PLoS ONE 7(2):e31474
Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS (2001) Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 345(14):1022–1029
Lund J, Qin QP, Ilva T, Nikus K, Eskola M, Porela P, Kokkala S, Pulkki K, Pettersson K, Voipio-Pulkki LM (2006) Pregnancy-associated plasma protein A: A biomarker in acute ST-elevation myocardial infarction (STEMI). Ann Med 38(3):221–228
Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348(12):1104–1111
Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R (2008) Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 52(4):266–272
Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52(1):112–119
Voors AA, Von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, Van Veldhuisen DJ, Dickstein K (2009) C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 30(10):1187–1194
Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T (2009) Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 54(1):60–68
Wollert KC, Kempf T (2012) Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep 9(4):337–345
Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98(3):342–350
Kempf T, Björklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, Tongers J, Wollert KC, Wallentin L (2007) Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 28(23):2858–2865
Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H (2007) Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50(11):1054–1060
Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT (2007) IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Investig 117(6):1538–1549
Weinberg EO, Shimpo M, Hurwitz S, Tominaga S-i, Rouleau J-L, Lee RT (2003) Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107(5):721–726
Rehman SU, Mueller T, Januzzi JL (2008) Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52(18):1458–1465
Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O’Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR (2007) Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50(7):607–613
López B, Ravassa S, González A, Zubillaga E, Bonavila C, Bergés M, Echegaray K, Beaumont J, Moreno MU, San José G (2016) Myocardial collagen crosslinking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol 67(3):251–260
George J, Patal S, Wexler D, Roth A, Sheps D, Keren G (2005) Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150:484–487
Buralli S, Dini FL, Ballo P, Conti U, Fontanive P, Duranti E, Metelli MR, Marzilli M, Taddei S (2010) Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol 105(6):853–856
Frantz S, Störk S, Michels K, Eigenthaler M, Ertl G, Bauersachs J, Angermann C (2008) Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 10(4):388–395
Ibrahim NE, Januzzi JL Jr (2017) Beyond natriuretic peptides for diagnosis and management of heart failure. Clin Chem 63(1):211–222
Tziakas DN, Chalikias GK, Stakos D, Chatzikyriakou SV, Papazoglou D, Mitrousi K, Lantzouraki A, Thomaidi A, Boudoulas H, Konstantinides S (2011) Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. Eur J Prev Cardiol 19(1):62–71
Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, Adourian A, Böhm M, van Veldhuisen DJ, Komajda M (2012) Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 33(18):2290–2296
van Kimmenade RR, Januzzi JL, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48(6):1217–1224
Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, Gaggin HK, Bhardwaj A, Januzzi JL (2013) Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 15(10):1157–1163
Ryu J-A, Yang JH, Lee D, Park C-M, Suh GY, Jeon K, Cho J, Baek SY, C. Carriere K, Chung CR, (2015) Clinical usefulness of procalcitonin and C-reactive protein as outcome predictors in critically ill patients with severe sepsis and septic shock. PLoS ONE 10(9):e0138150
Reiner MM, Khoury WE, Canales MB, Chmielewski RA, Patel K, Razzante MC, Cloughtery CO, Rowland DY (2017) Procalcitonin as a biomarker for predicting amputation level in lower extremity infections. J Foot Ankle Surg 56(3):484–491
Hayashida K, Kondo Y, Hara Y, Aihara M, Yamakawa K (2017) Head-to-head comparison of procalcitonin and presepsin for the diagnosis of sepsis in critically ill adult patients: a protocol for a systematic review and meta-analysis. BMJ Open 7(3):e014305
Peacock W, Hollander J, Diercks D, Lopatin M, Fonarow G, Emerman C (2008) Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 25(4):205–209
Manzano-Fernández S, Januzzi JL, Boronat-Garcia M, Bonaque-González JC, Truong QA, Pastor-Pérez FJ, Muñoz-Esparza C, Pastor P, Albaladejo-Otón MD, Casas T (2011) β-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. J Am Coll Cardiol 57(7):849–858
Nymo SH, Ueland T, Askevold ET, Flo T, Kjekshus J, Hulthe J, Wikstrand J, McMurray J, Van Veldhuisen DJ, Gullestad L (2012) The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA. J Intern Med 271(5):436–443
Macdonald S, Arendts G, Nagree Y, Xu X-F (2012) Neutrophil Gelatinase-Associated Lipocalin (NGAL) predicts renal injury in acute decompensated cardiac failure: a prospective observational study. BMC Cardiovasc Disord 12(1):1–6
Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 52(10):818–827
Loria V, Dato I, Graziani F, Biasucci LM (2008) Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediat Inflamm 2008:1–4
Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, Simoons ML, Hamm CW (2003) Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108(12):1440–1445
Zhang R, Brennan M-L, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL (2001) Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286(17):2136–2142
Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG (2009) Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem 55(8):1462–1470
Khan AA, Alsahli MA, Rahmani AH (2018) Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives. Med Sci 6(2):33
Welsh P, Woodward M, Rumley A, Lowe G (2008) Associations of plasma pro-inflammatory cytokines, Fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. Br J Haematol 141(6):852–861
Budzynski AZ, Shainoff JR (1986) Fibrinogen and fibrin: biochemistry and pathophysiology. Crit Rev Oncol Hematol 6(2):97–146
Canseco-Ávila LM, Jerjes-Sánchez C, Ortiz-López R, Rojas-Martínez A, Guzmán-Ramírez D (2006) Fibrinogen. Cardiovascular risk factor or marker? Arch Cardiol Mexico 76(S4):158–172
Galanakis DK (1992) Fibrinogen anomalies and disease: a clinical update. Hematol Oncol Clin North Am 6(5):1171–1187
Ussher JR, Lopaschuk GD, Arduini A (2013) Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis 231(2):456–461
Fogelman AM (2015) TMAO is both a biomarker and a renal toxin. Journal 116:396–397
Haidaris PJ, Francis CW, Sporn LA, Arvan DS, Collichio FA, Marder VJ (1989) Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of y chain-variant polypeptides. Blood 74(2):743–750
Singh T, Nigam A, Gupta A, Singh B (2011) Cardiac biomarkers: When to test?-physician perspective. JIACM 12(2):117–121
Eggers KM, Oldgren J, Nordenskjöld A, Lindahl B (2004) Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to Troponin I for exclusion of myocardial infarction. Am Heart J 148(4):574–581
Abadie JM, Blassingame CL, Bankson DD (2005) Albumin cobalt binding assay to rule out acute coronary syndrome. Ann Clin Lab Sci 35(1):66–72
Gaze DC (2009) Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet 24(4):333–341
El-Tamimi H, Mansour M, Wargovich T, Hill J, Kerensky R, Conti C, Pepine C (1994) Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease. Endothel Funct Revisit Circ 89(1):45–51
Lerman A, BurnettJr J (1992) Intact and altered endothelium in regulation of vasomotion. Circulation 86(6):III12-19
Reriani MK, Flammer AJ, Jama A, Lerman LO, Lerman A (2012) Novel functional risk factors for the prediction of cardiovascular events in vulnerable patients following acute coronary syndrome. Circ J 2012:1203141649–1203141649
Jodo S, Kobayashi S, Nt K, Ogura N, Feng Y, Amasaki Y, Fujisaku A, Azuma M, Yagita H, Okumura K (1997) Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 107(1):89–95
Takahashi K, Ohyabu Y, Takahashi K, Solodushko V, Takatani T, Itoh T, Schaffer SW, Azuma J (2003) Taurine renders the cell resistant to ischemia-induced injury in cultured neonatal rat cardiomyocytes. J Cardiovasc Pharmacol 41(5):726–733
Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263(5154):1759–1762
Cowland JB, Borregaard N (1997) Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 45(1):17–23
Friedl A, Stoesz S, Buckley P, Gould M (1999) Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J 31(7):433–441
Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK (2002) The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 10(5):1033–1043
Devarajan P (2008) NGAL in acute kidney injury: from serendipity to utility. Am J Kidney Dis 52(3):395–399
Yndestad A, Landrø L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Frøland SS, Husberg C, Christensen G (2009) Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 30(10):1229–1236
Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, Van Veldhuisen DJ, Montagna L, Cosmi F, Tognoni G (2011) Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 32(21):2705–2712
Fabbrini E, Serafini M, Baric IC, Hazen SL, Klein S (2014) Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes 63(3):976–981
Jin YL, Zhu T, Xu L, Zhang WS, Liu B, Jiang CQ, Yu H, Huang LM, Cheng KK, Thomas GN (2013) Uric acid levels, even in the normal range, are associated with increased cardiovascular risk: the Guangzhou Biobank Cohort Study. Int J Cardiol 168(3):2238–2241
Dutta A, Henley W, Pilling LC, Wallace RB, Melzer D (2013) Uric acid measurement improves prediction of cardiovascular mortality in later life. J Am Geriatr Soc 61(3):319–326
Zhao G, Huang L, Song M, Song Y (2013) Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis 231(1):61–68
Fenech G, Rajzbaum G, Mazighi M, Blacher J (2014) Serum uric acid and cardiovascular risk: state of the art and perspectives. Joint Bone Spine 81(5):392–397
Jee SH, Lee SY, Kim MT (2004) Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men. Eur J Cardiovasc Prev Rehabil 11(3):185–191
Lee K-F, Simon H, Chen H, Bates B, Hung M-C, Hauser C (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378(6555):394–398
Kuramochi Y, Cote GM, Guo X, Lebrasseur NK, Cui L, Liao R, Sawyer DB (2004) Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1β/erbB4 signaling. J Biol Chem 279(49):51141–51147
Lemmens K, Doggen K, De Keulenaer GW (2007) Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 116(8):954–960
Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB (2001) Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women’s health and aging study. Circulation 103(7):947–953
Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G (2004) Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 109(6):726–732
Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson P-A, Smith U (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354(24):2552–2563
Alkharfy KM, Al-Daghri NM, Vanhoutte PM, Krishnaswamy S, Xu A (2012) Serum retinol-binding protein 4 as a marker for cardiovascular disease in women. PLoS ONE 7(10):e48612
Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kominami G, Kita T (2010) Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome—comparison with other biomarkers. J Cardiol 56(2):159–165
Heilbronn K, Smith R, Ravussin E (2003) The insulin-sensitizing role of the fat derived hormone adiponectin. Curr Pharm Des 9(17):1411–1418
Shimada K, Miyazaki T, Daida H (2004) Adiponectin and atherosclerotic disease. Clin Chim Acta 344(1–2):1–12
Wang X-j, Wang M (2010) The S100 protein family and its application in cardiac diseases. World J Emerg Med 1(3):165
Zhan Y, Yu J, Ding R, Sun Y, Hu D (2014) Triglyceride to high density lipoprotein cholesterol ratio, total cholesterol to high density lipoprotein cholesterol ratio and low ankle brachial index in an elderly population. Vasa 43(3):189–197
Fekih O, Triki S, Hellara I, Neffati F, Rejeb J, Ommezzine A, Chouchane S, Guediche MN, Bouslama A, Najjar MF (2014) Can paraoxonase 1 polymorphisms (L55 M and Q192 R) protect children with type 1 diabetes against lipid abnormalities? J Clin Lipidol 8(3):249–255
Shah SN, Arneja J (2013) Efficacy of rosuvastatin in achieving target HDL, LDL, triglycerides and total cholesterol levels in type 2 diabetes mellitus (T2DM) with newly diagnosed dyslipidaemia: an open label, nonrandomized, non-interventional and observational study in India. J Assoc Physicians India 61(10):721–726
Merino J, Masana L, Guijarro C, Ascaso J, Lagares M, Civeira F (2014) Recomendations for clinical use of food enriched phytosterols/phytostanols handling hypercholesterolemia. ClínInvestig Arterioscler 26(3):147–158
Hoogeveen EK, Geleijnse JM, Kromhout D, van’t Sant P, Gemen EF, Kusters R, Giltay EJ (2015) No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: the Alpha Omega Trial. Eur J Prev Cardiol 22(5):648–655
Hirayama S, Miida T (2012) Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta 414:215–224
Topbas C, Swick A, Razavi M, Anderson NL, Pearson TW, Bystrom C (2018) Measurement of lipoprotein-associated phospholipase A2 by use of 3 different methods: exploration of discordance between ELISA and activity assays. Clin Chem 64(4):697–704
Investigators S (2014) Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 370(18):1702–1711
Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Hagström E, Harrington RA, Hochman JS, Koenig W (2016) Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease. J Am Heart Assoc 5(6):e003407
Tourdot BE, Ahmed I, Holinstat M (2014) The emerging role of oxylipins in thrombosis and diabetes. Front Pharmacol 4:176
Idzikowska K, Zielińska M (2018) Midregional pro-atrial natriuretic peptide, an important member of the natriuretic peptide family: potential role in diagnosis and prognosis of cardiovascular disease. J Int Med Res 46(8):3017–3029
Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D (2008) Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 52(1):10–29
Parati G, Stergiou GS, Asmar R, Bilo G, De Leeuw P, Imai Y, Kario K, Lurbe E, Manolis A, Mengden T (2008) European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 26(8):1505–1526
Barwari T, Joshi A, Mayr M (2016) MicroRNAs in cardiovascular disease. J Am Coll Cardiol 68(23):2577–2584
Dimmeler S, Zeiher AM (2010) Circulating microRNAs: novel biomarkers for cardiovascular diseases? Journal 31:2705–2707
Karakas M, Schulte C, Appelbaum S, Ojeda F, Lackner KJ, Münzel T, Schnabel RB, Blankenberg S, Zeller T (2017) Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study. Eur Heart J 38(7):516–523
Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard J-M, Mayr A, Weger S, Schett G, Shah A (2012) Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 60(4):290–299
Kim AJ, Ro H, Kim H, Chang JH, Lee HH, Chung W, Jung JY (2021) Soluble ST2 and galectin-3 as predictors of chronic kidney disease progression and outcomes. Am J Nephrol 52(2):119–130
Li C, Zhao M, Zhao M, Chen N, Guo Y, Du Y, Zhang Y, Cao B, Zhan B, Guo C (2022) IL-37 isoform D acts as an inhibitor of soluble ST2 to boost type 2 immune homeostasis in white adipose tissue. Cell Death Discov 8(1):1–12
Karthigan N, Lockwood S, White A, Yang J, Young MJ (2022) Mineralocorticoid receptor antagonists, heart failure and predictive biomarkers. J Endocrinol 253(3):R65–R70
Mincarone P, Bodini A, Tumolo MR, Vozzi F, Rocchiccioli S, Pelosi G, Caselli C, Sabina S, Leo CG (2021) Discrimination capability of pretest probability of stable coronary artery disease: a systematic review and meta-analysis suggesting how to improve validation procedures. BMJ Open 11(7):e047677
Kanmura S, Morinaga Y, Tanaka A, Komaki Y, Iwaya H, Kumagai K, Mawatari S, Sasaki F, Tanoue S, Hashimoto S (2021) Increased gene copy number of DEFA1A3 is associated with the severity of ulcerative colitis. Clin Transl Gastroenterol 12(4):e00331